Other
Non-Hodgkin Lymphoma by Clinical Course
CI-CAN-00003432Explore in graph →
Hematologic346 active trials12 approved drugs7 evidence items
- NCIt
- C7215
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00003432Explore in graph →
Clinical trials
1,200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (209)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05914662 | Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM(ZBR) | unknown | Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05422066 | Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma | unknown | Phase 2 | 50 | Li ZhimingOTHER | 1 | Jun 17, 2024 | clinicaltrials |
| NCT06406556 | Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL(ENKTL) | unknown | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06224842 | Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL | unknown | Phase 1 / Phase 2 | 30 | Huijing WuOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT03697356 | R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia(Ballondor) | unknown | Phase 2 | 54 | Kosin University Gospel HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT05979948 | A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia(CZ-WM01) | unknown | Phase 2 | 60 | Shanghai Changzheng HospitalOTHER | 1 | Sep 14, 2023 | clinicaltrials |
| NCT05941156 | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia | unknown | Phase 2 | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 12, 2023 | clinicaltrials |
| NCT05576532 | Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia | unknown | Phase 2 | 30 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05774028 | Pegaspargase Combined With Gemcitabine, Etoposide, Liposomal Mitoxantrone Hydrochloride and Dexamethasone (P-GEMD) in the Treatment of Untreated Early Non-upper Respiratory Tract or Advanced Extranodal NK/T-cell Lymphoma | unknown | Phase 2 | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 0 | Mar 17, 2023 | clinicaltrials |
| NCT05543070 | Low-dose Radiotherapy in iNHL | unknown | Phase 2 | 73 | Chinese Academy of Medical SciencesOTHER | 1 | Sep 16, 2022 | clinicaltrials |
| NCT03671850 | VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients | unknown | Phase 2 | 48 | ViGenCell Inc.INDUSTRY | 1 | Apr 29, 2022 | clinicaltrials |
| NCT03853044 | Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma | unknown | Phase 2 | 23 | Ruijin HospitalOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02481310 | Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma | unknown | Phase 1 / Phase 2 | 38 | Northwestern UniversityOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT05179213 | Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma | unknown | Phase 2 | 20 | Peking Union Medical College HospitalOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT05149170 | Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL | unknown | Phase 2 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Dec 8, 2021 | clinicaltrials |
| NCT03439501 | Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] | unknown | Phase 2 | 21 | Samsung Medical CenterOTHER | 1 | Sep 24, 2021 | clinicaltrials |
| NCT05049473 | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. | unknown | Phase 2 | 100 | PETHEMA FoundationOTHER | 1 | Sep 20, 2021 | clinicaltrials |
| NCT04917250 | GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma | unknown | Phase 2 | 15 | Beijing Tongren HospitalOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT04899414 | Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell Lymphoma | unknown | Phase 2 | 50 | Peking UniversityOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT02689869 | Combination of PCI-32765 With Obinutuzumab in Untreated Follicular Lymphoma(Alternative) | unknown | Phase 2 | 98 | Ludwig-Maximilians - University of MunichOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04831710 | Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL | unknown | Phase 2 | 83 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03156101 | A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects | unknown | Phase 1 / Phase 2 | 24 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04431089 | Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma | unknown | Phase 2 | 122 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 28, 2021 | clinicaltrials |
| NCT02544425 | VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT)(VIDL+ASCT) | unknown | Phase 2 | 27 | Samsung Medical CenterOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04279379 | Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT04337593 | Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL | unknown | Phase 2 | 20 | Beijing Tongren HospitalOTHER | 0 | Apr 7, 2020 | clinicaltrials |
| NCT04096690 | Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma | unknown | Phase 2 | 22 | Ruijin HospitalOTHER | 1 | Mar 11, 2020 | clinicaltrials |
| NCT02533700 | CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL | unknown | Phase 2 | 106 | Shandong Provincial HospitalOTHER_GOV | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03185494 | Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22 | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT03776279 | A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma | unknown | Phase 2 | 106 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Dec 14, 2018 | clinicaltrials |
| NCT02542124 | NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) | unknown | Phase 2 | 10 | Neumedicines Inc.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03679455 | A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1(OBI-1) | unknown | Phase 2 | 30 | Polish Myeloma ConsortiumOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03701022 | PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma | unknown | Phase 2 | 61 | Peking UniversityOTHER | 0 | Oct 9, 2018 | clinicaltrials |
| NCT03598959 | Tofacitinib Combined With Chidamide in R/R ENKTCL | unknown | Phase 2 | 20 | Sichuan UniversityOTHER | 1 | Jul 26, 2018 | clinicaltrials |
| NCT03564704 | Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL | unknown | Phase 2 / Phase 3 | 80 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jun 21, 2018 | clinicaltrials |
| NCT01719835 | CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study(CHEMO-T) | unknown | Phase 2 | 87 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT03391739 | CART-19 Cells For R/R B-ALL(CCFRRBA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT02560441 | Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type | unknown | Phase 2 | — | Chinese Academy of Medical SciencesOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT03154918 | GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma | unknown | Phase 2 | 60 | Sichuan UniversityOTHER | 1 | Nov 8, 2017 | clinicaltrials |
| NCT03335098 | Study of VTD in Waldenstrom's Macroglobulinemia(BOMB-THROW) | unknown | Phase 2 | 15 | Seoul National University HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT03273452 | Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)(PET) | unknown | Phase 2 | 30 | Qingdao UniversityOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT03261349 | Antiviral Agent HARVONI® for the Treatment of HCV-associated Indolent B-Cell Lymphoma | unknown | Phase 2 | 21 | National Taiwan University HospitalOTHER | 0 | Aug 25, 2017 | clinicaltrials |
| NCT02981745 | Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | unknown | Phase 1 / Phase 2 | 200 | Centaurus Biopharma Co., Ltd.INDUSTRY | 1 | Jul 19, 2017 | clinicaltrials |
| NCT03107962 | Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma | unknown | Phase 2 | 20 | Mingzhi ZhangOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT02685670 | Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma(MatchCART) | unknown | Phase 1 / Phase 2 | 20 | The Second Affiliated Hospital of Henan University of Traditional Chinese MedicineOTHER | 1 | Mar 16, 2017 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02881749 | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides | unknown | Phase 2 | 68 | Thomas Jefferson UniversityOTHER | 0 | Aug 30, 2016 | clinicaltrials |
| NCT02878278 | Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation | unknown | Phase 2 | 24 | Huiqiang HuangOTHER | 0 | Aug 25, 2016 | clinicaltrials |
| NCT02080234 | Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01735604 | Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Sep 29, 2015 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2024source: clinicaltrials